Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
D Gyrase Subunit B (EC 5.99.1.3) - Overview
D Gyrase Subunit B (EC 5.99.1.3) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
D Gyrase Subunit B (EC 5.99.1.3) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
D Gyrase Subunit B (EC 5.99.1.3) - Companies Involved in Therapeutics Development
Abgentis Ltd
AstraZeneca Plc
Daiichi Sankyo Co Ltd
Spero Therapeutics Inc
D Gyrase Subunit B (EC 5.99.1.3) - Drug Profiles
DS-11960558 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DS-2969 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GYR-12 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit D Gyrase B and D Topoisomerase IV for Gram Negative Bacterial Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SPR-720 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VXC-100 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
D Gyrase Subunit B (EC 5.99.1.3) - Dormant Products
D Gyrase Subunit B (EC 5.99.1.3) - Product Development Milestones
Featured News & Press Releases
Dec 04, 2019: Spero reports prelimiry findings from phase 1 clinical trial of SPR720 and announces plans to advance program into proof-of-concept clinical trial in patients with NTM Pulmory Disease
Nov 26, 2019: Spero Therapeutics provides new update on SPR720
Jun 17, 2019: Spero Therapeutics to present data for all pipeline programs including SPR-720 at the ASM Microbe 2019 Conference
Feb 26, 2019: Spero Therapeutics receives QIDP Desigtion from the U.S. FDA for the Development of SPR720
Jan 30, 2019: Spero starts Phase I trial of SPR720 for NTM infections
Nov 05, 2018: Spero Therapeutics announces positive results from SPR720 IND-Ebling studies and plans to initiate a phase 1 Trial
Jun 05, 2018: Spero Therapeutics to Present Data On SPR720 at ASM Microbe 2018
May 30, 2017: Spero Therapeutics Presents New Data on SPR720 at ASM Microbe 2017
May 04, 2017: Spero Therapeutics Receives Grant from tiol Institutes of Health to Explore Novel Treatment Combitions for Tuberculosis
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019


List of Tables


Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indication, H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Abgentis Ltd, H2 2019
Pipeline by AstraZeneca Plc, H2 2019
Pipeline by Daiichi Sankyo Co Ltd, H2 2019
Pipeline by Spero Therapeutics Inc, H2 2019
Dormant Projects, H2 2019